Uniqure NV
QURE24.810USD
-0.380-1.51%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.54BMarket Cap
LossP/E TTM
More Details of Uniqure NV Company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Uniqure NV Info
Ticker SymbolQURE
Company nameUniqure NV
IPO dateFeb 05, 2014
CEOKapusta (Matthew)
Number of employees209
Security typeOrdinary Share
Fiscal year-endFeb 05
AddressPaasheuvelweg 25a
CityAMSTERDAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1105 BP
Phone31202406000
Websitehttps://www.uniqure.com/
Ticker SymbolQURE
IPO dateFeb 05, 2014
CEOKapusta (Matthew)
Company Executives of Uniqure NV
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
--
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
32.06K
-32.72%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
20.27K
+40.66%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
15.67K
-22.96%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
--
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
32.06K
-32.72%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 7
Updated: Sun, Dec 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.90%
Avoro Capital Advisors LLC
7.13%
RTW Investments L.P.
7.10%
EcoR1 Capital, LLC
6.40%
abrdn Inc.
4.72%
Other
65.73%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.90%
Avoro Capital Advisors LLC
7.13%
RTW Investments L.P.
7.10%
EcoR1 Capital, LLC
6.40%
abrdn Inc.
4.72%
Other
65.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
39.47%
Investment Advisor
26.44%
Hedge Fund
19.09%
Corporation
3.83%
Research Firm
3.16%
Individual Investor
1.48%
Venture Capital
1.48%
Pension Fund
0.92%
Private Equity
0.89%
Other
3.23%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
368
55.15M
89.53%
-7.50M
2025Q2
396
55.26M
101.06%
-1.58M
2025Q1
429
55.29M
101.00%
-4.83M
2024Q4
431
46.57M
86.23%
-10.92M
2024Q3
431
43.93M
89.29%
-10.96M
2024Q2
435
37.07M
76.08%
-15.19M
2024Q1
449
38.56M
80.27%
-17.69M
2023Q4
454
43.54M
90.77%
-8.61M
2023Q3
462
41.52M
86.64%
-16.34M
2023Q2
452
41.43M
87.10%
-18.53M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
802.61K
1.3%
-47.04K
-5.54%
Jun 30, 2025
Avoro Capital Advisors LLC
3.63M
5.88%
+1.45M
+66.67%
Jun 30, 2025
RTW Investments L.P.
5.16M
8.37%
+892.80K
+20.93%
Jun 30, 2025
EcoR1 Capital, LLC
3.99M
6.48%
--
--
Jun 30, 2025
abrdn Inc.
2.75M
4.47%
+535.16K
+24.15%
Jun 30, 2025
Bristol Myers Squibb
2.39M
3.88%
--
--
Sep 30, 2024
Franklin Advisers, Inc.
1.61M
2.61%
-382.31K
-19.23%
Jun 30, 2025
State Street Investment Management (US)
1.14M
1.86%
-86.78K
-7.06%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.25M
2.03%
-53.87K
-4.12%
Jun 30, 2025
Two Sigma Investments, LP
1.60M
2.6%
+15.67K
+0.99%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Global X Genomics & Biotechnology ETF
3.77%
WisdomTree BioRevolution Fund
3.51%
Virtus LifeSci Biotech Clinical Trials ETF
2.87%
Invesco NASDAQ Future Gen 200 ETF
2.23%
Alger Mid Cap 40 ETF
2.06%
State Street SPDR S&P Biotech ETF
1.37%
Direxion Daily S&P Biotech Bull 3X Shares
0.84%
ProShares Ultra Nasdaq Biotechnology
0.36%
Invesco Nasdaq Biotechnology ETF
0.36%
Franklin Genomic Advancements ETF
0.34%
View more
Global X Genomics & Biotechnology ETF
Proportion3.77%
WisdomTree BioRevolution Fund
Proportion3.51%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion2.87%
Invesco NASDAQ Future Gen 200 ETF
Proportion2.23%
Alger Mid Cap 40 ETF
Proportion2.06%
State Street SPDR S&P Biotech ETF
Proportion1.37%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.84%
ProShares Ultra Nasdaq Biotechnology
Proportion0.36%
Invesco Nasdaq Biotechnology ETF
Proportion0.36%
Franklin Genomic Advancements ETF
Proportion0.34%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Uniqure NV?
The top five shareholders of Uniqure NV are:
Fidelity Management & Research Company LLC holds 802.61K shares, accounting for 1.30% of the total shares.
Avoro Capital Advisors LLC holds 3.63M shares, accounting for 5.88% of the total shares.
RTW Investments L.P. holds 5.16M shares, accounting for 8.37% of the total shares.
EcoR1 Capital, LLC holds 3.99M shares, accounting for 6.48% of the total shares.
abrdn Inc. holds 2.75M shares, accounting for 4.47% of the total shares.
Fidelity Management & Research Company LLC holds 802.61K shares, accounting for 1.30% of the total shares.
Avoro Capital Advisors LLC holds 3.63M shares, accounting for 5.88% of the total shares.
RTW Investments L.P. holds 5.16M shares, accounting for 8.37% of the total shares.
EcoR1 Capital, LLC holds 3.99M shares, accounting for 6.48% of the total shares.
abrdn Inc. holds 2.75M shares, accounting for 4.47% of the total shares.
What are the top three shareholder types of Uniqure NV?
The top three shareholder types of Uniqure NV are:
Fidelity Management & Research Company LLC
Avoro Capital Advisors LLC
RTW Investments L.P.
Fidelity Management & Research Company LLC
Avoro Capital Advisors LLC
RTW Investments L.P.
How many institutions hold shares of Uniqure NV (QURE)?
As of 2025Q3, 368 institutions hold shares of Uniqure NV, with a combined market value of approximately 55.15M, accounting for 89.53% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -11.53%.
What is the biggest source of revenue for Uniqure NV?
In --, the -- business generated the highest revenue for Uniqure NV, amounting to -- and accounting for --% of total revenue.
